Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of “Buy” by Brokerages

Scholar Rock Holding Corporation (NASDAQ:SRRK) has earned an average rating of “Buy” from the seventeen brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $56.00.

A number of research firms have issued reports on SRRK. JPMorgan Chase & Co. lifted their target price on Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 16th. Citigroup lifted their target price on Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Barclays lifted their target price on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Wedbush lifted their target price on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday, April 1st. Finally, Piper Sandler lifted their target price on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday, March 4th.

Scholar Rock Stock Down 2.3%

Shares of NASDAQ SRRK opened at $44.30 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. Scholar Rock has a 52 week low of $27.07 and a 52 week high of $52.19. The stock has a market capitalization of $5.31 billion, a P/E ratio of -12.34 and a beta of 0.69. The stock’s fifty day moving average is $48.00 and its 200 day moving average is $45.63.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period in the prior year, the company posted ($0.67) earnings per share. Sell-side analysts forecast that Scholar Rock will post -3.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Scholar Rock news, COO Keith Woods sold 10,220 shares of Scholar Rock stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the transaction, the chief operating officer owned 620,055 shares in the company, valued at $30,736,126.35. The trade was a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Hallal sold 30,615 shares of Scholar Rock stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $1,517,585.55. Following the completion of the transaction, the chief executive officer owned 1,639,034 shares in the company, valued at approximately $81,246,915.38. This represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 63,491 shares of company stock worth $3,147,249. Insiders own 13.30% of the company’s stock.

Institutional Trading of Scholar Rock

Hedge funds and other institutional investors have recently made changes to their positions in the company. IFP Advisors Inc grew its holdings in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Scholar Rock during the fourth quarter worth about $30,000. Summit Securities Group LLC bought a new stake in shares of Scholar Rock during the fourth quarter worth about $31,000. EverSource Wealth Advisors LLC grew its holdings in shares of Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Scholar Rock during the fourth quarter worth about $44,000. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).